AstraZeneca's liver cancer therapy combo slows disease progression in late-stage trial

AstraZeneca reported that a combination treatment with its cancer drug Imfinzi produced a significant improvement in progression-free survival in a late-stage trial for a common liver cancer. The positive Phase III result de-risks and strengthens Imfinzi's oncology franchise and could materially improve commercial prospects if supported by regulatory filings and approvals.

Analysis

AstraZeneca reported that a combination treatment with its cancer drug Imfinzi produced a significant improvement in progression-free survival in a late-stage trial for a common liver cancer. The positive Phase III result de-risks and strengthens Imfinzi's oncology franchise and could materially improve commercial prospects if supported by regulatory filings and approvals.